EDITAS MEDICINE, INC. Restricted Cash and Cash Equivalents, Current
EDITAS MEDICINE, INC. (EDIT) had Restricted Cash and Cash Equivalents, Current of $3.90 million as of 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Balance Sheet › Assets › Assets, Current › Restricted Cash and Investments, Current
us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue · last filed 2022-02-24
- 2021-12-31: Restricted Cash and Cash Equivalents, Current $3.90M.
- 2020-12-31: Restricted Cash and Cash Equivalents, Current $3.90M.
- 2019-12-31: Restricted Cash and Cash Equivalents, Current $1.60M.
- 2018-12-31: Restricted Cash and Cash Equivalents, Current $1.60M.
| Period end | Restricted Cash and Cash Equivalents, Current | Restricted Cash and Cash Equivalents, Current as first filed |
|---|---|---|
| 2021-12-31 | $3.90M 10-K · filed 2022-02-24 | |
| 2020-12-31 | $3.90M 10-K · filed 2021-02-26 | |
| 2019-12-31 | $1.60M 10-K · filed 2020-02-26 | |
| 2018-12-31 | $1.60M 10-K · filed 2019-03-01 | |
| 2017-12-31 | $1.60M 10-K · filed 2019-03-01 | |
| 2016-12-31 | $1.60M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $300.00K 10-K · filed 2018-03-08 | $320.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |